In casualty insurance, providing for menopause treatment coverage.
Impact
The implementation of SB1122 is expected to enhance access to crucial healthcare resources for individuals experiencing menopause. By ensuring that health insurance plans cover various treatment options, the bill aims to provide comprehensive support for managing symptoms related to menopause. This move aligns with a broader effort to improve women's health care in Pennsylvania and may lead to improved health outcomes as individuals will be less burdened by out-of-pocket costs for necessary treatments.
Summary
Senate Bill 1122, also known as the Menopause Treatment Coverage Act, aims to amend the Pennsylvania Insurance Company Law to include specific coverage requirements for menopause treatment within health insurance policies. This legislation mandates that all health insurance policies offered, issued, or renewed in Pennsylvania must cover both hormonal and non-hormonal treatments for managing menopausal symptoms. Included in the required coverage are FDA-approved drugs, devices, behavioral therapy, and therapy addressing menopause induced by hysterectomy procedures.
Contention
While the bill is generally viewed positively among advocates for women's health, there may be points of contention regarding cost implications and how insurance providers implement these coverage requirements. Some stakeholders may express concerns over the financial effects on health insurers or the potential for increased premiums. Moreover, the specifics surrounding cost-sharing arrangements for these treatments may also generate debate, particularly regarding what constitutes 'medical necessity' and how it affects access to care.
Providing for medical assistance coverage and insurance coverage of screening, prevention and treatment measures for osteoporosis as a result of menopause.